French 
English 
Chinese 
Russian MSC Therapy for Chronic Kidney Disease: What the 2025 Evidence Shows
A 2025 meta-analysis of 52 studies, real-world Taiwan data, and Mayo Clinic intraarterial delivery results — what nephrologists need to know about MSCs and CKD.
14Oct
28Août
Essais cliniques sur les cellules souches mésenchymateuses : ce que l’ISCT de Dublin a révélé sur la réparation du ménisque, le transfert mitochondrial et l’approvisionnement en cellules
A medical review of MSC clinical trials 2026: key evidence from ISCT Dublin, a Japanese phase III synovial-MSC meniscal repair trial, bone marrow vs cord tissue OA data, and mitochondrial EV mechanisms.
20Août
MSC Therapy for Multiple Sclerosis: What 17 Trials and Tell Us
MSCs are the most promising cell therapy in progressive MS, and 2026 added the mechanism papers and one well-controlled trial that finally make the case. Here’s what 17 trials, SMART-MS, and the new miRNA work mean for real patients.
18Août
MSC Therapy for Diabetic Foot Ulcers: 2026 Mechanism, Hydrogel Delivery, and Real-World Trial Outcomes
2026 medical update on MSC therapy for diabetic foot ulcers: M2 macrophage polarization, EXO-miR3671 angiogenesis, hydrogel delivery, UC-MSC vs ADSC head-to-head, 47-RCT meta-analysis, and cost-effectiveness vs amputation in Thailand.
12Août
MSC Therapy for Degenerative Disc Disease: A 2026 Meta-Analysis of Randomized Trials and the Cell-Free Exosome Frontier
A 2026 meta-analysis of 7 randomized trials confirms intradiscal MSC injections reduce chronic back pain and disability significantly. Meanwhile, bioengineered exosome therapies are redefining what cell-free disc regeneration looks like.
19Juin
Intravenous UC-MSCs for Ischemic Stroke: What the MERIT Phase 1 Trial Tells Us
The MERIT phase 1 trial published in Cell Reports Medicine shows that intravenous UC-MSC therapy is safe in subacute ischemic stroke, with early NIHSS improvement signals. Here’s what clinicians need to know.